|
|
|
Scientists Still Can’t Be Trusted on Gene Editing
Pete Shanks, The Progressive Magazine | 12.04.2023
Five years on from the shocking discovery of He Jiankui’s rogue gene editing experiment, some scientists continue to forge ahead with heritable genome editing. With more indications than ever that scientists can’t be trusted on heritable gene editing, public discussion and calls for a moratorium or ban are increasingly urgent.
|
| |
|
|
Sharing our gratitude
We are so grateful for the overwhelming support our CGS community showed this Giving Tuesday. We raised nearly $6,000 to power the fight for genetic justice! Our end-of-year giving campaign is off to a great start. Can you help propel us into 2024 with a donation today?
| | |
|
|
A look at the international race to create human eggs and sperm in the lab
Rob Stein, Regina G. Barber, Berly McCoy, NPR | 11.29.2023
“Combining [lab-made gametes] and genome editing and commercialization” is a “toxic stew” that would “create people… supposedly biologically superior to others. We don't want to pave the road toward any kind of future that looks anything like that,” said CGS’ Marcy Darnovsky.
| | |
|
|
CRISPR therapies heading to the clinic
Katie Hasson, Biopolitical Times | 12.13.2023
Approval of the first CRISPR-based gene therapy in the US and UK shows the promise of gene editing to treat patients—and highlights big questions about safety, effectiveness, and access that remain.
| |
|
GENE EDITING | EUGENICS
ASSISTED REPRODUCTION | SURROGACY360 | VARIOUS
| |
|
Gene therapy offered this 7-year-old freedom. The price: a grueling year
Brittany Trang, STAT | 12.13.2023
A newly developed gene therapy for beta thalassemia is described as a “one-time” infusion. The treatment process is arduous and lengthy, though, requiring months in the hospital, a course of chemotherapy, and isolation from others to let the immune system recover.
| |
|
The ethical dilemma of gene editing: Our reporter took your questions
Carolyn Y. Johnson, The Washington Post | 12.12.2023
Linking to a CGS blog post by Pete Shanks, Johnson notes that “multiple rounds of international meetings have reaffirmed that gene editing is not ready to make heritable edits. Many countries have outlawed heritable gene editing.”
| |
|
The first CRISPR cure might kick-start the next big patent battle
Antonio Regalado, MIT Technology Review | 12.01.2023
Vertex, the company that developed the newly approved therapy for sickle cell disease, doesn’t own the US patent on editing human cells with CRISPR, and will likely face a lawsuit from the patent holders asking for royalties from the therapy and possibly damages.
| |
|
The CRISPR Era Is Here
Sarah Zhang, The Atlantic | 11.27.2023
The approval of a CRISPR gene therapy for sickle cell disease is a landmark advance for gene therapies. However, the long-term durability and safety of gene editing are still unknown.
| |
|
Superintelligent AI — Transhumanism etc
Madhumita Murgia and John Thornhill, Financial Times | 12.05.2023
Some tech entrepreneurs and engineers attempting to advance artificial general intelligence adhere to transhumanist ideologies that rely on a eugenicist and racist foundation.
| |
|
Why Anonymous Sperm Donation Is Over, and Why That Matters
Emily Bazelon, The New York Times Magazine | 12.03.2023
Some donor-conceived activists are advocating for government bans on anonymous gamete donation, but some LGTBQ parents worry that disclosure laws could undermine LGBTQ families, in part by opening the door to biological donors being recognized as parents.
| | |
|
|
Ministers approve plans to recognise international surrogacy for first time
The Irish Times | 12.12.2023
The Irish government passed legislation recognizing international surrogacy, both retrospectively and in the future. The law specifies a process intended parents must go through and a set of criteria for surrogacy arrangements. It also establishes a new regulatory agency.
|
|
|
White House targets drug patents in latest effort to lower prices
Washington Post Staff, Washington Post | 12.07.2023
The White House has proposed a new plan to lower drug prices: if the federal government determines that a manufacturer has set the price of a drug too high, regulators could step in to license the drug to a competing manufacturer.
| | | | |
